Regd. Office: F.P 145, Ram Mandir Road, Vile Parle (East), Mumbai - 400 057

CIN - U65910MH1989PTC053111, Tel.: 022-43242149

April 6, 2017

National Stock Exchange of India Limited

Exchange Plaza Plot No. C/1, G Block Bandra Kurla Complex Bandra (East), Mumbai 400 051.

NSE Scrip Code: SUNPHARMA

Dear Sirs,

BSE Limited

Phiroze Jeejeebhoy Towers **Dalal Street** Mumbai 400 001.

BSE Scrip Code: 524715

Subject: Notice under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations")

We, Shanghvi Finance Private Limited, being an entity holding equity shares of Sun Pharmaceutical Industries Limited ("Sun Pharma") as part of the promoter group, have acquired from individuals being the promoter and part of promoter group of Sun Pharma, by way of 'inter-se' transfer, the equity shares of the entities ("Holding Companies") which are collectively holding controlling stake in entities which are holding equity shares of Sun Pharma as part of the promoter group amounting to indirect acquisition of equity shares of Sun Pharma under Regulation 3 read with Regulation 5 of the Takeover Regulations. The said acquisition is pursuant to inter-se transfer of shares amongst qualifying persons as specified in Regulation 10(1)(a)(ii) and 10(1)(a)(iii) of Takeover Regulations.

The Form as prescribed under Regulation 10(6) of the Takeovers Regulations setting out the details of the said indirect acquisition of shares of Sun Pharma by way of inter-se transfer is enclosed herewith.

The necessary disclosure under Regulation 10(5) for the above said acquisition, in the prescribed format, have already been submitted vide letter dated March 22, 2017.

Kindly take the information on record.

Thanking you,

Yours faithfully,

For Shanghvi Finance Private Limited ('Acquirer')

Sunil Ajmera Director

DIN: 00065545

トナナナアニ

Regd. Office: F.P 145, Ram Mandir Road, Vile Parle (East), Mumbai - 400 057

CIN - U65910MH1989PTC053111, Tel.: 022-43242149

Format for Disclosures under Regulation 10(6) – Intimation to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1	Nai (TC	me of the Target Company)	Sun Pharmaceutical Industries Limited ("Sun Pharma")		
2	Nai	me of the acquirer(s)	Shanghvi Finance Private Limited		
3	1	me of the stock exchange ere shares of the TC are ed	National Stock Exchange of India Limited (NSE) BSE Limited (BSE)		
4	incl	ails of the transaction uding rationale, if any, for transfer/acquisition of res.	This is an indirect acquisition of shares and voting rights of Sun Pharma by the Acquirer. Pursuant to inter-se transfer of shares as a part of internal restructuring of shareholding of promoter and promoter group in the TC, the Acquirer has acquired equity shares of entities ("Holding Companies") which are collectively holding controlling stake in entities which are holding equity shares of the TC as part of the promoter group. Please refer Annexure A for number of shares of Holding Companies acquired by the Acquirer.		
5	whi	evant regulation under ich the acquirer is mpted from making open er.	Regulation 10(1)(a)(ii) and 10(1)(a)(iii) of SEBI (SAST) Regulations, 2011.		
6	pr re	hether disclosure of oposed acquisition was quired to be made under gulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the	Yes, disclosure was made within the timeline specified under the regulations. March 22, 2017		
		stock exchange.	Widi 611 22, 2017		
7	Details of acquisition		Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made	
	a.	Name of the transferor / seller	Mr. Dilip Shantilal Shanghvi and Mrs. Vibha Dilip Shanghvi	Mr. Dilip Shantilal Shanghvi and Mrs. Vibha Dilip Shanghvi	
	b.	Date of acquisition	On or after March 30, 2017	March 30, 2017	
	C.	Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	The Acquirer will not directly acquire equity shares of TC but intends to acquire equity shares of entities ("Holding Companies") which are	The Acquirer has not directly acquired equity shares of TC but has acquired equity shares of entities ("Holding Companies") which are	



Regd. Office: F.P 145, Ram Mandir Road, Vile Parle (East), Mumbai - 400 057

CIN - U65910MH1989PTC053111, Tel.: 022-43242149

	d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	collectively controlling stake which are holdi shares of the TC the promoter gro refer Annexure number of s Holding Compan acquired by the A Indirect acquisitio 42.098% equity sl voting rights of TC	ing equity as part of oup. Please A for hares of ies to be acquirer. on of hares /	collectively holding controlling stake in entities which are holding equity shares of the TC as part of the promoter group. Please refer Annexure A for number of shares of Holding Companies acquired by the Acquirer. Indirect acquisition of 42.098% equity shares / voting rights of TC	
	e.	Price at which shares are proposed to be acquired / actually acquired	indirect acquisition of ar shares of TC. The price at which the equity shares of Holding Companies which are collectively holding controlling stake in entities which are holding equity where sof the TC as part of the promoter group is the		As stated above, this was an indirect acquisition of shares of TC. The price, at which the equity shares of Holding Companies which are collectively holding controlling stake in entities which are holding equity shares of the TC as part of the promoter group, is provided in Annexure A.	
8	Sha	reholding details	Pre-Transaction		Post-Transaction	
			No. of shares held	% w.r.t. total share capital of TC	No. of shares held	% w.r.t. total share capital of TC
	A	Each Acquirer / Transferee (*) Shanghvi Finance Private Limited	2,82,603	0.01	2,82,603#	0.01
		TOTAL (a)	2,82,603	0.01	2,82,603	0.01
					-	
	В	Each Seller / Transferor Mr. Dilip Shantilal Shanghvi	23,02,85,690	9.60	23,02,85,690#	9.60
		Mrs. Vibha Dilip Shanghvi	88,40,280	0.37	88,40,280 [#]	0.37
		TOTAL (b)	23,91,25,970	9.97	23,91,25,970	9.97

As this was an indirect acquisition of shares of TC, there is no change in direct shareholding of the Acquirer and the Sellers in TC. However, as detailed in Annexure A, the Acquirer has acquired equity shares of Holding Companies which are collectively holding controlling stake in entities which are holding equity shares of the TC as part of the promoter group.

Regd. Office: F.P 145, Ram Mandir Road, Vile Parle (East), Mumbai - 400 057

CIN - U65910MH1989PTC053111, Tel.: 022-43242149

Note:

- (*) Shareholding of each entity may be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

Før Shanghvi Finance Private Limited ('Acquirer')

Sunil Ajmera Director

DIN: 00065545

Place: Mumbai Date: April 6, 2017

Regd. Office: F.P 145, Ram Mandir Road, Vile Parle (East), Mumbai - 400 057

CIN - U65910MH1989PTC053111, Tel.: 022-43242149

Annexure A: Details about the indirect acquisition

This disclosure is being made for indirect acquisition of shares / voting rights of Sun Pharma by the Acquirer.

Details of acquisition of equity shares of Holding Companies by the Acquirer from the Sellers:

No.	Name of the Holding Companies whose shares have been acquired by the Acquirer	Sellers	No. of Equity Shares	% shareho Iding	Price at which shares of Holding Companies are acquired
1	Alrox Investment and	Mr. Dilip Shanghvi	9,70,600	98.28	Rs. 385/-
	Finance Private Limited	Mrs. Vibha Shanghvi	17,000	1.72	
2	Airborne Investment and Finance Private Limited	Mr. Dilip Shanghvi	9,70,720	98.28	Rs. 10/-
		Mrs. Vibha Shanghvi	17,000	1.72	
3	Bridgestone Investment	Mr. Dilip Shanghvi	9,66,000	98.27	Rs. 31/-
	and Finance Private Limited	Mrs. Vibha Shanghvi	17,000	1.73	
4	Deeparadhana Investment	Mr. Dilip Shanghvi	9,66,000	98.27	Rs. 30/-
	and Finance Private Limited	Mrs. Vibha Shanghvi	17,000	1.73	
5	Mackinon Investment and	Mr. Dilip Shanghvi	9,66,000	98.27	Rs. 38/-
	Finance Private Limited	Mrs. Vibha Shanghvi	17,000	1.73	

The above acquisition of equity shares of the aforesaid Holding Companies by the Acquirer from the Sellers has led to holding of indirect controlling stake in below entities which are holding equity shares of Sun Pharma as part of the promoter group thus leading to indirect acquisition of shares/voting rights in Sun Pharma:

No.	Name of the entities	Number of shares held in Sun	% of
		Pharma	shareholding
1.	Viditi Investment Private Limited	20,08,46,362	8.371
2.	Tejaskiran Pharmachem Industries Private Limited	19,48,20,971	8.120
3.	Family Investment Private Limited	18,24,37,880	7.604
4.	Quality Investments Private Limited	18,23,79,237	7.601
5.	Virtuous Finance Private Limited	9,68,51,821	4.037
6.	Virtuous Share Investments Private Limited	8,37,51,259	3.491



Regd. Office: F.P 145, Ram Mandir Road, Vile Parle (East), Mumbai - 400 057

CIN - U65910MH1989PTC053111, Tel.: 022-43242149

	Total	1,01,00,44,785	42.098
13.	Nirmit Exports Private Limited	7,022	0.000
	Private Limited		
12.	Asawari Investment and Finance	49,468	0.002
11	Package Investrade Private Limited	8,95,039	0.037
10.	Jeevanrekha Investrade Private Limited	14,58,806	0.061
9.	Unimed Investments Limited	1,04,00,850	0.434
8.	Sholapur Organics Private Limited	1,59,92,110	0.667
7.	Aditya Medisales Limited	4,01,53,960	1.674

For Shanghvi Finance Private Limited ('Acquirer')

Sunil Ajmera Director

DIN: 00065545

Place: Mumbai Date: April 6, 2017